Loading
Every dated change on the records linked to Metastatic pheochromocytoma and paraganglioma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Progression-free survival at 12 months 36 percent with sunitinib against 19 percent with placebo, meeting the primary endpoint of the first randomised trial in the disease.
A milestone in how this cancer is treated.
Alpha-blockade with beta-blockade added second; metyrosine for refractory symptoms; blockade before every procedure; bone-protective agents for skeletal metastases.
Active surveillance; resection, radiotherapy, thermal ablation or embolisation of dominant or symptomatic lesions.
Lutetium-177 dotatate for somatostatin-receptor-positive disease; 131I-MIBG for MIBG-avid disease where still available (approved 2018, withdrawn from market 2024).
Belzutifan (approved 2025); sunitinib (FIRSTMAPPP); cabozantinib; cyclophosphamide, vincristine and dacarbazine or temozolomide for rapidly progressive or SDHB-related disease.
68Ga-DOTATATE PET, 123I-MIBG scintigraphy where 131I-MIBG is available, CT or MRI, FDG-PET for SDHB-related disease; germline testing.
ONC206, radioligand combinations and next-generation HIF-2 alpha inhibitors.